CO-ALEPH-OBJECTS
12.6.2019 07:02:29 CEST | Business Wire | Press release
Aleph Objects, Inc., manufacturer of LulzBot 3D Printers, announced their collaboration with FluidForm Inc., an innovator in 3D bioprinting. FluidForm’s FRESH printing technique, developed in Carnegie Mellon University’s Regenerative Biomaterials and Therapeutics Group, enables 3D printing of bioinks and other soft materials. Together, Aleph Objects and FluidForm will combine their expertise to offer new bioprinting solutions, with the initial offering coming this summer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611006066/en/
3D bioprinting is already being used in labs to create tissue scaffolds and other complex biological structures. “We’re still at the very beginning of being able to build real functional tissues with 3D bioprinting,” said FluidForm CTO Adam Feinberg. “Collaborations like the one we are building with LulzBot will help make this a reality faster.”
3D biofabrication technology is revolutionizing applications across a wide spectrum of industries, including pharmaceuticals, regenerative medicine, drug screening, food and other animal products, cell-based biosensors, and testing of cosmetics and other health care goods. Within the next decade, major pharmaceutical companies will be able to replace some animal testing and non-physiological 2D cell culture systems with clinically-relevant 3D bioprinted human tissues.
FluidForm’s novel platform of Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D printing enables fabrication of soft, biological scaffolds for applications in tissue engineering and regenerative medicine.
“Combining proven expertise in professional 3D printers and hardware with 3D biofabrication technology is going to be an absolute game-changer,” said Aleph Objects CEO and President Grant Flaharty. “The market for 3D bioprinters and 3D bioprinted tissues is estimated to grow to $1.9 billion by 2028.”
Subscribe and be the first to learn about LulzBot’s bioprinting advancements and new products! https://www.lulzbot.com/Bio
About Aleph Objects, Inc.
Aleph Objects, Inc. is the Colorado-based designer and manufacturer of the award-winning line of LulzBot® 3D Printers. LulzBot is a trusted brand in Automotive, Consumer Products, Aerospace/Defense, Medical, and Education industries around the globe. Aleph Object’s core company values of Free Software, Libre Innovation, and Open Source Hardware enable users to uniquely modify both software and hardware to bring their imagination to life. For more information, visit www.LulzBot.com .
Media Assets: https://own.alephobjects.com/s/XeJkaLJWHSzByib
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611006066/en/
Contact:
Press Contact: Eric Beardslee press@lulzbot.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Announces Segment Leadership Appointments30.6.2026 13:30:00 CEST | Press release
Xylem Inc. (NYSE: XYL), a leading global water solutions company, today announced two executive leadership appointments, effective July 1, both reporting to President and Chief Executive Officer Matthew Pine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630087773/en/ Meredith Emmerich has been appointed EVP and President, Measurement and Control Solutions at Xylem. Meredith Emmerich has been appointed EVP and President, Measurement and Control Solutions. Most recently, she served as EVP and President, Applied Water at Xylem. Emmerich joined Xylem in 2024 from Carrier Global Corporation (NYSE: CARR), where she was Vice President of Global Enterprise Solutions and held several senior leadership roles, including leading the Americas Commercial HVAC business and the Global Residential, Light Commercial, and VRF HVAC portfolio. Emmerich succeeds Mike McGann, who will serve as senior advisor to ensure a smooth and orderly tra
Strike Europe Secures Full MiCA Authorization, Unlocking Bitcoin Services Across All 27 EU Member States30.6.2026 13:29:00 CEST | Press release
Strike is now available to millions of customers across the European Union Strike, a leading Bitcoin financial services company, today announced that its European entity, Zap (Strike) Europe Limited, has been authorized as a crypto-asset service provider by the Malta Financial Services Authority (MFSA) under the EU's Markets in Crypto-Assets Regulation (MiCA) and the Malta Markets in Crypto Assets Act (Cap. 647, laws of Malta) to provide crypto-asset services. The license enables millions of Europeans across all 27 EU member states to access Strike's suite of Bitcoin financial services under a single regulatory framework, replacing the patchwork of national regimes that previously governed the market. Strike has served eligible European customers since April 2024. The MFSA authorization makes that presence permanent and EU-wide, and positions the company among a small group of firms to complete the MiCA process to date. "Europe deserves a Bitcoin-only company focused on doing one thing
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 13:17:00 CEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus
L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release
The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release
Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom